Biopharma AI
By
How Did Novartis’ 2025 Deals Shape Its Strategic Direction and What Might They Signal for 2026?
Novartis’ deal activity in 2025 reflected a deliberate and strategic effort to strengthen its scientific platforms, broaden its…
How Did AbbVie’s 2025 Deals Shape Its Year, and What Do They Signal for Growth in 2026?
NORTH CHICAGO, IL — As 2025 concludes, AbbVie Inc. reflects on a year of strategic dealmaking that complements…
Did AbbVie Successfully Manage 2025 Headwinds, and Are Rinvoq and Skyrizi Poised to Reach $31B+ Sales by 2027?
NORTH CHICAGO, ILLINOIS — As 2025 comes to a close, AbbVie reflects on a year marked by strong…
Pfizer’s Strategic Deals in 2025: Key Moves Shaping the Company’s Next Phase
Strategic Takeaways In 2025, Pfizer executed a series of focused and strategic deals aimed at strengthening its pipeline,…
Is Owkin Building the Clinical Data Intelligence Layer as Pharma Commits Over $1.5 Billion to Federated AI Partnerships?
Strategic Overview Owkin is positioning itself at the center of a critical bottleneck in drug development: access to…
Is Isomorphic Labs Becoming Pharma’s Foundational AI Platform as Partnerships Surpass $3 Billion and Alphabet Commits $600 Million?
Strategic Overview Isomorphic Labs is emerging as one of the most structurally important AI companies in drug discovery—less…
